dr. ellis on measuring endocrine therapy efficacy with ki67
Published 12 years ago • 267 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:52
dr. ellis discusses ki67 as a treatment monitoring biomarker
-
1:25
dr. ellis on neoadjuvant endocrine therapy for breast cancer
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
1:12
dr. matthew ellis on heterogeneity impacting biomarker efficacy
-
0:50
dr. ellis discusses the cell-proliferation marker ki67
-
13:02
dr. matthew ellis on hormonal therapy before breast cancer surgery
-
1:00
dr. ellis considers the use of biosimilars in oncology
-
1:24
dr. ellis on adjuvant cdk4/6 inhibition in hr-positive breast cancer
-
0:20
copy of dr. ellis on the entrance of biosimilars into the field of oncology
-
1:35
dr. ellis describes breast cancer heterogeneity
-
2:05
dr. ellis on potential impact of cdk4/6 inhibitors in breast cancer
-
0:22
copy of dr. ellis on abemaciclib in hr-positive breast cancer
-
1:32
dr. ellis discusses genome forward breast cancer treatment
-
0:59
dr. ellis discusses the future of the pi3-kinase pathway
-
1:55
dr. matthew ellis on the future of tcga
-
0:58
dr. ellis on anticipated er /her2- breast cancer paradigms
-
1:32
dr. ellis discusses the falcon trial
-
3:53
ki-67: explained!!! #medschooldiscussion
-
2:33
challenges with neoadjuvant endocrine therapy in breast cancer